| Literature DB >> 31272790 |
Alessandra Ammazzalorso1, Laura De Lellis2, Rosalba Florio3, Antonio Laghezza4, Barbara De Filippis5, Marialuigia Fantacuzzi5, Letizia Giampietro5, Cristina Maccallini5, Paolo Tortorella4, Serena Veschi3, Fulvio Loiodice4, Alessandro Cama6, Rosa Amoroso5.
Abstract
The reduced activation of PPARs has a positive impact on cancer cell growth and viability in multiple preclinical tumor models, suggesting a new therapeutic potential for PPAR antagonists. In the present study, the benzothiazole amides 2a-g were synthesized and their activities on PPARs were investigated. Transactivation assay showed a moderate activity of the novel compounds as PPARα antagonists. Notably, in cellular assays they exhibited cytotoxicity in pancreatic, colorectal and paraganglioma cancer cells overexpressing PPARα. In particular, compound 2b showed the most remarkable inhibition of viability (greater than 90%) in two paraganglioma cell lines, with IC50 values in the low micromolar range. In addition, 2b markedly impaired colony formation capacity in the same cells. Taken together, these results show a relevant anti-proliferative potential of compound 2b, which appears particularly effective in paraganglioma, a rare tumor poorly responsive to chemotherapy.Entities:
Keywords: Amides; Anti-proliferative; Benzothiazoles; Cytotoxicity; PPAR antagonists; Paraganglioma
Year: 2019 PMID: 31272790 DOI: 10.1016/j.bmcl.2019.06.020
Source DB: PubMed Journal: Bioorg Med Chem Lett ISSN: 0960-894X Impact factor: 2.823